PTX3 was assayed at randomization and after 3 months in 1,233 patients from the GISSI-Heart Failure trial (GISSI-HF) and 1,457 patients from the Controlled Rosuvastatin Multinational Trial in HF (CORONA) (72). Here, PTX3 is linked to heart failure.